- Stocks
- Pharma & Healthcare
- Bandaram Pharma
Bandaram Pharma share price
NSE: BANDARAMPharma & HealthcarePackaging & Containers
Bandaram Pharma at a glance
With a market capitalisation of ₹53 Cr, it ranks 3038th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Packaging & Containers.
Its return on equity was 1.1% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹26 Cr (+209.3% year on year) and net profit ₹0 Cr (−26.7%), on a consolidated basis. Promoters held 62.66% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹53 CrRank 3038 on NSE
- Price to book
- 1.58×FY26
- EPS (TTM)
- ₹0.21to Q4 FY26
- ROE
- 1.1%FY26
- ROCE
- 4.7%FY26
- Debt to equity
- 0.89FY26
- Net profit margin
- 0.4%FY26
- Book value / share
- ₹14.90FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Bandaram Pharma quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹11 Cr | ₹7 Cr | ₹10 Cr | ₹8 Cr | ₹8 Cr | ₹14 Cr | ₹15 Cr | ₹26 Cr |
| Revenue YoY | +93.7% | +47.5% | +2.0% | −36.8% | −28.8% | +93.0% | +48.4% | +209.3% |
| Net profit | ₹0 Cr | ₹1 Cr | −₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net profit YoY | +157.1% | +458.3% | −101.8% | −21.1% | −88.9% | −91.0% | — | −26.7% |
| Net margin | 1.6% | 9.4% | −0.1% | 1.8% | 0.2% | 0.4% | 2.4% | 0.4% |
| EPS | ₹0.15 | ₹0.56 | −₹0.01 | ₹0.13 | ₹0.01 | ₹0.03 | ₹0.11 | ₹0.06 |
Bandaram Pharma financials
| Item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹19 Cr | ₹34 Cr | ₹37 Cr | — |
| Operating profit | ₹0 Cr | ₹1 Cr | ₹1 Cr | — |
| Net profit | ₹0 Cr | ₹1 Cr | ₹1 Cr | — |
| EPS (₹) | ₹0.00 | ₹1.00 | ₹1.00 | — |
| Cash from operations | ₹0 Cr | −₹4 Cr | −₹5 Cr | — |
| Total debt | ₹8 Cr | ₹5 Cr | ₹9 Cr | ₹10 Cr |
| Shareholders' equity | ₹3 Cr | ₹12 Cr | ₹13 Cr | ₹27 Cr |
Bandaram Pharma shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 6 Nov 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 62.62% | 62.62% | 62.66% | 62.66% |
| Domestic institutions | 0.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Non-institutions | 24.99% | 25.00% | 37.37% | 37.37% | 37.33% | 37.33% |
Bandaram Pharma vs peers
The listed Pharma & Healthcare companies nearest to Bandaram Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| CONSTRONICConstronics Inf | — | — | — | ₹57 Cr | — | — |
| KABRADGKabra Drugs | — | — | — | ₹56 Cr | — | — |
| BANDARAMBandaram Pharma | — | — | — | ₹53 Cr | — | — |
| VRLVasundhara Ras | — | — | — | ₹53 Cr | — | — |
| VIVIMEDLABVivimed Labs | ₹6.21 | −1.90% | −45.8% | ₹51 Cr | — | — |
| SHREEPACShree Pacetroni | — | — | — | ₹50 Cr | — | — |
| BIOFILCHEMBiofil Chemicals & Pharmaceuticals | ₹30.00 | +2.15% | −27.3% | ₹49 Cr | 17.5 | — |
Ask anything about Bandaram Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against BANDARAM's own history. Try: “Why has BANDARAM moved over the last three months?” · “Backtest a 50-day moving-average crossover on BANDARAM over five years” · “Compare BANDARAM with CONSTRONIC on margins and valuation”
Frequently asked questions about Bandaram Pharma
What is the market cap of Bandaram Pharma?
Bandaram Pharma's market capitalisation is ₹53 Cr (₹53 Cr) at the 22 Oct 2026 close, ranking 3038th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Bandaram Pharma?
Return on equity was 1.1% in FY26 and return on capital employed was 4.7% in FY26 (consolidated figures).
Is Bandaram Pharma a debt-free company?
No. Bandaram Pharma's debt-to-equity ratio was 0.89 in FY26, with total debt of ₹10 Cr.
What were Bandaram Pharma's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Bandaram Pharma reported revenue of ₹26 Cr, +209.3% year on year, and net profit of ₹0 Cr, −26.7% year on year.
What is the shareholding pattern of Bandaram Pharma?
As of 30 Jun 2026: promoters 62.66%, domestic institutions 0.00%, non-institutions 37.33%.
Who are Bandaram Pharma's competitors?
The listed Pharma & Healthcare companies closest to Bandaram Pharma by market cap are Constronics Inf, Kabra Drugs, Vasundhara Ras, Vivimed Labs, Shree Pacetroni and Biofil Chemicals & Pharmaceuticals.
Is Bandaram Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Bandaram Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BANDARAM against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with B · all NSE stocks · this page as text